Cryo-Cell International, Inc. CCEL
AMEX
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.02% | -1.93% | -3.59% | -2.26% | -2.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.02% | -1.93% | -3.59% | -2.26% | -2.99% |
| Cost of Revenue | -10.45% | -9.68% | -16.53% | 272.27% | -15.26% |
| Gross Profit | 3.10% | 0.45% | 0.71% | -72.60% | 1.40% |
| SG&A Expenses | -2.51% | 8.46% | 8.05% | -9.34% | -6.88% |
| Depreciation & Amortization | -0.65% | -3.05% | -4.17% | -6.22% | -4.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.97% | 2.22% | 0.07% | 44.97% | -11.26% |
| Operating Income | 15.43% | -19.78% | -27.55% | -3,143.50% | 36.74% |
| Income Before Tax | 53.91% | 43.94% | -86.83% | -449.86% | -14.05% |
| Income Tax Expenses | 27.12% | 24.58% | -90.75% | -179.92% | 33.03% |
| Earnings from Continuing Operations | 69.54% | 55.87% | -83.35% | -105.06% | -28.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.54% | 55.87% | -83.35% | -105.06% | -28.74% |
| EBIT | 15.43% | -19.78% | -27.55% | -3,143.50% | 36.74% |
| EBITDA | 13.51% | -17.32% | -22.60% | -3,039.07% | 31.05% |
| EPS Basic | 69.46% | 56.36% | -83.43% | -105.33% | -28.68% |
| Normalized Basic EPS | 27.20% | -20.60% | -44.85% | -414.52% | 60.90% |
| EPS Diluted | 75.11% | 72.00% | -80.67% | -105.33% | -30.77% |
| Normalized Diluted EPS | 27.43% | -20.16% | -44.08% | -414.52% | 62.80% |
| Average Basic Shares Outstanding | 0.06% | -0.31% | -0.33% | -0.14% | -0.05% |
| Average Diluted Shares Outstanding | -0.11% | -0.86% | -1.75% | -0.14% | -1.22% |
| Dividend Per Share | -- | -- | -- | -100.00% | -- |
| Payout Ratio | -- | -- | -- | 1.00% | -- |